Monoclonal and Polyclonal Antibodies Research

Isolation of Secretory Immunoglobulin A (sIgA) from nasal secretions collected in saline and Viral Transport Medium.

The paper describes a method to isolate sIgA1 from nasal secretions using jacalin-conjugated beads, confirming its identity via Western blotting and highlighting its potential as a biomarker for nasal vaccine evaluation.

Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells

The paper develops anti-VHH antibodies that target nanobody domains in CAR-T cells, enabling labeling, blocking, and activation of VHH-based CAR-T cells without disrupting antigen binding.

Better antibodies engineered with a GLIMPSE of human data

GLIMPSE-1, a protein language model trained on human antibody sequences, improves antibody engineering for affinity, cross-reactivity, and developability by leveraging patterns in the human repertoire.

Cancer therapy via neoepitope-specific monoclonal antibody cocktails

This paper demonstrates the use of neoepitope-specific monoclonal antibody cocktails to treat B16F10 melanoma by targeting unique tumor mutations, showing in vitro and in vivo efficacy.

Germline polymorphism in the immunoglobulin kappa and lambda loci explain variation in the expressed light chain antibody repertoire

This study shows that genetic variations in immunoglobulin light chain loci influence the diversity of expressed light chain antibodies, affecting amino acid sequences and gene usage.

Targeted fusion of Antibody-Secreting Cells: unlocking monoclonal antibody production with hybridoma technology

This study improves monoclonal antibody production by targeting specific antibody-secreting cells, achieving a 100% fusion yield and over 60% mAb secretion.

Computational design of monomeric Fc variants with distinct pH-responsive FcRn-binding profiles

The paper computationally designs monomeric Fc variants with distinct pH-responsive FcRn-binding profiles, showing enhanced binding at acidic pH and weak binding at neutral pH.

Quantitative pharmacology methods for bispecific T cell engagers

The paper develops a quantitative pharmacology model to analyze how TCE drug-target trimer formation and biodistribution depend on binding kinetics and design characteristics.

Towards pharmacokinetic profile predictions for monoclonal antibodies using sequence based machine learning derived parameters and compartmental modeling

This paper predicts pharmacokinetic profiles of monoclonal antibodies using sequence-based machine learning and compartmental modeling, achieving accurate predictions with reduced reliance on animal testing.

Efficient Design of Affilin(R) Protein Binders for HER3

This study combines AI/physics-based computation and phage display to design high-affinity Affilin(R) proteins targeting HER3, achieving successful theranostic candidates with high affinity and stability.

Generation of a Synthetic Single Domain Antibody Library for Radiopharmaceutical Ligand Discovery

This paper develops a synthetic nanobody library for radiopharmaceutical ligand discovery, demonstrating its utility through PET imaging of a calreticulin-binding nanobody.

A kinetic model of antigen-dependent IgG oligomerization and complement binding

This paper develops a kinetic model to predict IgG oligomerization and complement binding, incorporating factors like IgG concentration, antigen density, and Fc mutants.

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases

This study develops and characterizes humanized TNFα inhibitory nanobodies with picomolar potency and low immunogenicity for therapeutic use in TNFα-mediated diseases.

Protease-Containing Nanobodies for Detecting and Manipulating Intracellular Antigens Using Antiviral Drugs

The paper introduces protease-containing nanobodies controlled by antiviral drugs to manipulate intracellular protein-protein interactions.

AbBFN2: A flexible antibody foundation model based on Bayesian Flow Networks

AbBFN2 is a generative antibody foundation model that unifies diverse data sources and enables flexible conditional generation for multiple antibody design tasks.

FlowDesign: Improved Design of Antibody CDRs Through Flow Matching and Better Prior Distributions

FlowDesign improves antibody CDR design using flow matching and better priors, achieving higher affinity and neutralizing potency against HIV mutants.

Factors Influencing Monoclonal Antibody Pharmacokinetics Across Varying Immune Perturbations

This study evaluates the pharmacokinetics of a human mAb in different mouse strains to identify suitable models for preclinical testing.

Focused learning by antibody language models using preferential masking of non-templated regions

This paper introduces a preferential masking strategy for antibody language models to improve prediction of non-templated residues in CDR3 regions, enhancing classification and specificity.

Co-phagocytosis of VEGFA with HER2-overexpressing cancer cells induced by HER2-VEGFA BsAb improves antitumor responses

This paper demonstrates that HER2-VEGFA bispecific antibodies induce co-phagocytosis of VEGFA and HER2-overexpressing cancer cells, enhancing antitumor responses in preclinical models.

Nanobodies as therapies for loss-of-function misfolding diseases.

This study develops and characterizes six nanobodies as potential therapeutics for PH1 by targeting misfolded AGT variants, showing high affinity and functional enhancement in cellular models.

Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder Cancer

The paper identifies ITGA3B1 as a therapeutic target for metastatic bladder cancer using a phenotypic screening strategy and develops an ADC targeting this integrin complex, showing antitumor efficacy in preclinical models.

Mapping affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactions

The paper maps the affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactions by analyzing amino acid variations and their effects on binding and effector functions.

Fab-arm exchange affects each and all endogenous serum IgG4 evenly

The paper introduces an LC-MS method to analyze IgG4 repertoires with clonal resolution, revealing high diversity and persistence of IgG4 molecules in serum over time.

A humanized 16A antibody conjugated with DNA topoisomerase I inhibitors, targeting a GSTA glycosite-signature epitope.

This paper evaluates the antitumor efficacy of humanized 16A antibody conjugates with DNA topoisomerase I inhibitors, showing potent in vitro and in vivo activity against MUC1-expressing tumors.

Data-driven evaluation of suitable immunogens for improved antibody selection

This study evaluates immunogen properties to improve antibody selection by analyzing structural and functional features and developing a tool for applying these insights.

Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti-CD19-AntiCD3 Diabody

The paper develops a sensitive GLP-compliant ELISA for detecting GP101 diabody in mouse serum, achieving 15pg/mL sensitivity.

Design, Construction, and Validation of a Yeast-Displayed Chemically Expanded Antibody Library

This paper describes a yeast-displayed chemically expanded antibody library and demonstrates its use in identifying function-disrupting antibodies through initial screening.

Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen

This paper describes the design and characterization of a bispecific monocyte engager targeting PSMA for prostate cancer immunotherapy, showing effective activation of monocytes and tumor cell elimination.

Development of novel high-affinity nanobodies against EGFR for cancer therapy

This paper isolates and characterizes two high-affinity nanobodies against EGFR, showing their potent anti-tumor activity in vitro.

A rapid non-traditional approach for developing biologicals against drug- resistant bacteria and yeasts.

The paper presents a rapid method to develop anti-infective biologicals effective against drug-resistant bacteria and yeasts using antibody-drug conjugates with dual modes of action.